LOUISVILLE, Colo., Jan. 28, 2013 – GlobeImmune, Inc., today announced the initiation of a Phase 1a clinical trial to investigate the safety and immunogenicity of GI-13020 in healthy volunteers. The GI-13020 Tarmogen®, which GlobeImmune is developing in collaboration with Gilead … Continue reading
GlobeImmune Initiates Phase 1a Clinical Trial of GI-13020 in Healthy Volunteers
January 28, 2013